The Sofosbuvir/Daclatasvir oral combo demonstrated 100% SVR24 rates in GT2/GT3 patients (Phase 2 / n=14).
Note that in that phase II of sofosbuvir + daclatasvir w/wo ribavirin treatment duration was 24 weeks in GT2/3 and perhaps there were other differences like cirrhotic patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.